2017
Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis
Foer D, Zhu M, Cardone RL, Simpson C, Sullivan R, Nemiroff S, Lee G, Kibbey RG, Petersen KF, Insogna KL. Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis. Osteoporosis International 2017, 28: 2011-2017. PMID: 28283687, PMCID: PMC6693506, DOI: 10.1007/s00198-017-3977-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood GlucoseCase-Control StudiesCholesterol, LDLFemaleGain of Function MutationGlucose Tolerance TestGlycated HemoglobinHomeostasisHumansIslets of LangerhansLipid MetabolismLow Density Lipoprotein Receptor-Related Protein-5MaleMiddle AgedTissue Culture TechniquesWnt Signaling PathwayConceptsLow-density lipoprotein receptor-related protein 5Insulin sensitivity indexType 2 diabetesInsulin secretionLRP5 mutationsLipid metabolismSerum LDLInsulin sensitivityLipid homeostasisGlucose metabolismAnimal modelsMean insulin sensitivity indexFunction mutationsHigh bone mass phenotypeLipoprotein receptor-related protein 5Augment insulin secretionGlucose-stimulated insulin secretionCoronary artery diseaseMajor risk factorCase-control studyImpaired insulin sensitivityHepatic lipid contentBone mass phenotypeProton magnetic resonance spectroscopyAcademic medical center
2014
Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5
Simpson CA, Foer D, Lee GS, Bihuniak J, Sun B, Sullivan R, Belsky J, Insogna KL. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5. Osteoporosis International 2014, 25: 2383-2388. PMID: 24927689, PMCID: PMC4659359, DOI: 10.1007/s00198-014-2767-5.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedBone DensityBone Morphogenetic ProteinsCase-Control StudiesFemaleGenetic MarkersGenotypeHumansIntercellular Signaling Peptides and ProteinsLow Density Lipoprotein Receptor-Related Protein-5MaleMiddle AgedMutationOsteoprotegerinProto-Oncogene ProteinsRANK LigandSex CharacteristicsWnt Signaling PathwayConceptsFrizzled-related protein 4Serum levelsWnt inhibitorsDickkopf-1Normal controlsUnrelated normal controlsHigh bone mass mutationsHigh bone mass syndromeFunction mutationsNormal age-matched controlsProtein 4Cross-sectional studyAge-matched controlsLRP5 resultSkeletal effectsEndogenous Wnt inhibitorsMass syndromeConsented volunteersUnrelated normal individualsDkk-1Different kindredsNormal individualsLRP5 signalingPatientsSclerostin
2013
Measurement of Plasma, Serum, and Platelet Serotonin in Individuals With High Bone Mass and Mutations in LRP5
Lee GS, Simpson C, Sun B, Yao C, Foer D, Sullivan B, Matthes S, Alenina N, Belsky J, Bader M, Insogna KL. Measurement of Plasma, Serum, and Platelet Serotonin in Individuals With High Bone Mass and Mutations in LRP5. Journal Of Bone And Mineral Research 2013, 29: 976-981. PMID: 24038240, PMCID: PMC3935983, DOI: 10.1002/jbmr.2086.Peer-Reviewed Original ResearchMeSH KeywordsBone DensityEnzyme-Linked Immunosorbent AssayFemaleHumansLow Density Lipoprotein Receptor-Related Protein-5MaleMiddle AgedMutationSerotoninConceptsLow-density lipoprotein receptor-related protein 5Age-matched controlsPlatelet-poor plasmaSerum serotonin levelsLRP5 mutationsSerotonin levelsBone massAffected individualsPlatelet pelletLipoprotein receptor-related protein 5Duodenal enterochromaffin cellsLevels of serotoninHigh bone massSecretion of serotoninMeasurement of plasmaSerum levelsEnterochromaffin cellsSubgroup analysisBlood serotoninPlatelet serotoninPossible associationSerotoninPoor plasmaGenetic deletionELISA